Disclosures: Athanasios Angelakis: Nothing to Disclose, Pietro Lampertico: ROCHE PHARMA/DIAGNOSTICS, GILEAD SCIENCES, GSK, ABBVIE, JANS: Advisor, Vana Sypsa: Nothing to Disclose, George Dalekos: Nothing to Disclose, Cihan Yurdaydin: Nothing to Disclose, Thomas Berg: Nothing to Disclose, IOANNIS GOULIS: Nothing to Disclose, Jose Luis Calleja: Nothing to Disclose, Harry Janssen: Gilead Sciences: and consultant, Gilead Sciences: Grant/Research Support, GlaxoSmithKline: Grant/Research Support, Janssen: Grant/Research Support, Roche: Grant/Research Support, Vir Biotechnology Inc.: Grant/Research Support, Aligos: Consultant, Gilead Sciences: Consultant, GlaxoSmithKline: Consultant, Grifols: Consultant, Roche: Consultant, Vir Biotechnology Inc: Consultant, Precision Biosciences: Consultant, Maria Buti: Nothing to Disclose, Nothing to Disclose, George Papatheodoridis: Abbvie: Advisor, Abbvie: Speaking and Teaching, Abbvie: Grant/Research Support, Astra Zeneca: Advisor, Astra Zeneca: Speaking and Teaching, Abbvie: Advisor, Abbvie: Speaking and Teaching, Astra Zeneca: Advisor, Astra Zeneca: Speaking and Teaching, Genesis: Advisor, Genesis: Speaking and Teaching, Gilead: Advisor, Gilead: Speaking and Teaching, Gilead: Grant/Research Support, GlaxoSmithKline: Advisor, Ipsen: Advisor, Ipsen: Speaking and Teaching, Novo Nordisk: Advisor, Novo Nordisk: Speaking and Teaching, Roche: Advisor, Roche: Speaking and Teaching, Takeda: Advisor 367 IMMUNE-RELATED ADVERSE EVENTS WITH LOW-DOSE NIVOLUMAB IN PATIENTS WITH CHRONIC HEPATITIS B: EXPERIENCE FROM 3 CLINICAL STUDIES Edward Gane 1 Tawesak Tanwandee 2 Bitna Yi 3 Teri Chew 3 Irina Botros 3 Danielle Shing 4 Heba Abdullah 3 Leonard Sowah 3 Frida Abramov 3 Ben Da 3 Audrey Lau 3 Anu Osinusi 3 Tak Yin Owen Tsang 5 Anchalee Avihingsanon 6 , 1 University of Auckland, Auckland, New Zealand, 2 Faculty of Medicine Siriraj Hospital, Bangkok, Thailand, 3 Gilead Sciences, Inc., Foster City, CA, USA, 4 Gilead Sciences, Inc., Cambridge, UK, 5 Infectious Disease Centre, Princess Margaret Hospital, Kwai Chung, Hong Kong, 6 HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand Background: Anti programmed death-1/programmed death ligand-1 (PD-1/PD-L1) monoclonal antibodies (mAbs) are being investigated at low doses for finite treatment of chronic hepatitis B (CHB) virus infection
If you are unsure about continuing the pregnancy, a healthcare provider can guide you through the process
Animal Data No teratogenic effects were observed when trazodone was given to pregnant rats and rabbits during the period of organogenesis at oral doses up to 450 mg/kg/day
Conclusion Alzheimers disease, as in other neurodegenerative diseases, has a systemic element that can affect peripheral cells outside the nervous system, characterized by a series of changes at the metabolic level, such as alterations in autophagy or mitochondrial dysfunction
